22.06.2023 • News

Röhm Seals Functional Forms Deal with SABIC

German PMMA specialist Röhm has signed a final agreement to acquire SABIC’s Functional form business, which makes high-end polycarbonate film and sheet.

Röhm is stemming the acquisition announced last December with support from its owner, private equity firm Advent International.

At the time, the Darmstadt-based company said the deal, for which financial terms have not been disclosed, was key to its strategy to advance its transparent semi-finished products business into a leading multi-polymer global player.

In future, CEO Michael Pack said, the company’s customers will be able to buy Röhm’s leading transparent PMMA brands Plexiglas and Acrylite as well as SABIC’s Lexan polycarbonate products from one supplier, while profiting from “unparalleled” technical and application expertise.

© Shutterstock/XXL Photo
© Shutterstock/XXL Photo

Adding the Lexan business – acquired by the Saudi group in the 2007 buyout of GE Plastics – not only further strengthens Röhm's leading position in transparent sheets, but also boosts its position in films and transportation, Pack said.

The Functional Form products are used across a wide variety of industries, ranging from building and construction to consumer electronics, medicine and aviation. The Saudi-owned business has some 700 employees and operations in 19 countries.

Author: Dede Williams, Freelance Journalist

Company

Logo:

Röhm GmbH

Deutsche-Telekom-Allee 9
64295 Darmstadt
Germany

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read